UnknownNot Applicable

Evaluation of Pcv-aCO2 in the Fluid Treatment of Abdominal Tumor Patients After Surgery

China150 participantsStarted 2016-10

Plain-language summary

This research will confirm that Pcv-aCO2 is suitable for the guidance of early fluid therapy and the evaluation of the prognosis of patients with abnormal hemodynamics after abdominal tumor surgery, and is expected to be a new monitoring index to improve the therapeutic effect of these patients.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Acute physiology and chronic health score system II (APACHE II) score ≥10；
✓. Hemodynamic abnormalities post-operation (a. systolic blood pressure\<90mmHg, or descent by basic blood pressure for more than 40mmHg. b. pulse pressure \<20mmHg, c. urine volume \<0.5ml/Kg/hr, d. heart rate \>100 / min, e.Central Venous Pressure(CVP) \<5mmHg, f. blood lactic acid \>2.7mmol/L, meet any one above).
✓. Age ≥ 18 years, which is expected to stay in ICU for 5 days or longer;
✓. Patients themselves or their authorized clients agree to participate in clinical trials and signed informed consent.

Exclusion criteria

✕. age \<18 years;
✕. without improvement in respiratory system disease or chronic obstructive pulmonary disease with Forced expiratory volume in one second (FEV1) \<50%;
✕. lobectomy and pneumonectomy;
✕. death within 24 after treatment;
✕. patients with severe organ dysfunction;
✕. pregnant or lactating women;
✕. the patients did not sign informed consent;
✕. any factors that may be expected to increase the risk of patients or other factors that may interfere with the results of clinical trials.

What they're measuring

The change of Pcv-aCO2

Timeframe: fluid resuscitation for 6 hours, 12 hours and 24 hours

Trial details

NCT IDNCT02977429

SponsorTianjin Medical University Cancer Institute and Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-01

Contact for this trial

Yang Yang, physician

022-23340123 yyicu3021@126.com

View on ClinicalTrials.gov More Abdominal Tumor trials